Newsletter Tool

PM Tracker

Today’s Big News

May 13, 2025

GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs

As Bayer's restructuring rolls on, Kerendia and Nubeqa power pharma division to surprising sales increase

Roche to spend $550M building Indianapolis HQ into CGM production hub

Mayne hit by misleading drug safety claims from the FDA ahead of $430M buyout

Arcturus stops work on early-stage vaccine programs in effort to ‘streamline resources’

Featured

GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs

By Nick Paul Taylor

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations.

As Bayer's restructuring rolls on, Kerendia and Nubeqa power pharma unit to surprising sales increase

By Kevin Dunleavy

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of blockbuster Xarelto in the first quarter.

Roche to spend $550M building Indianapolis HQ into CGM production hub

By Conor Hale

The announcement follows a five-year, $50-billion commitment from the Swiss pharma to expand its U.S. footprints in R&D and production.

Mayne hit by misleading drug safety claims from the FDA ahead of $430M buyout

By Nick Paul Taylor

Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral birth control pill in a presentation, triggering an untitled letter.

Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources'

By Ben Adams,Gabrielle Masson

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway.

Bluebird bio warns of potential bankruptcy as buyout faces another delay

By Angus Liu

Bluebird bio shareholders have dragged their feet in tendering shares as part of the company's sale process, prompting buyers Carlyle and SK Capital to extend their offer once again.

Fierce Biotech Layoff Tracker 2025: Leap halves team; Atara lays off 30% of staffers

By Gabrielle Masson,Darren Incorvaia

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

Novo heads to regulators after Sogroya matches predecessor Norditropin in 3 pediatric growth disorders

By Fraiser Kansteiner

Novo Nordisk has unveiled data from the phase 3 REAL8 trial, which found that the company’s once-weekly human growth hormone analogue Sogroya was largely on par with its daily predecessor, Norditropin, in a trio of growth disorders in kids.

Organon taps into ‘romantasy’ craze with new Nexplanon ad

By Andrea Park

Perhaps no literary genre has made quite as big of a splash in recent years as the fantasy-romance segment, colloquially known as “romantasy”—a phenomenon that Organon is capitalizing on in its newest ad campaign.

Roche spotlights Perjeta's staying power with 10-year breast cancer survival results

By Zoey Becker

After a decade of follow-up, Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer.

Trump administration axes $450M more in grant funding to Harvard

By Darren Incorvaia

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that has already been cut, according to a May 13 statement from the Joint Task Force to Combat Anti-Semitism.

Fierce podcasts

Don’t miss an episode

'The Top Line': Angela Hwang on her pivot from Big Pharma to biotech

This week on "The Top Line," Angela Hwang reflects on her leap from nearly 30 years at Pfizer to leading a biotech startup—and the career lessons that continue to guide her leadership and commitment to developing diverse talent.